 |
|
|
| |
SUSTAINED VIROLOGIC RESPONSE RATES AND VIRAL RESISTANCE PROFILES
WERE SIMILAR IN PATIENTS TREATED WITH A TELAPREVIR-BASED REGIMEN
REGARDLESS OF LIVER FIBROSIS STAGE
|
| |
| |
Reported by Jules Levin
22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), Taipei, Taiwan, February 16-19, 2012
Patrick Marcellin1, James C Sullivan2, Michael W Fried3, Tara L Kieffer2, Geoffrey M Dusheiko4, Emily C Martin2, David R Nelson5,
Adrian M Di Bisceglie6, Gregory T Everson7, Nathalie Adda2
1University of Paris Clichy, Clichy, France; 2Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 3University of
North Carolina at Chapel Hill, Chapel Hill, NC, USA; 4Royal Free and University College, London, United Kingdom;
5University of Florida, Gainesville, FL, USA; 6Saint Louis University School of Medicine, Saint Louis, MO, USA;
7University of Colorado, Denver, CO, USA
|
| |
|
|
|
|
|
